CAI · Investment summary · as of 12 August 2026
Priced below what the business already delivers
Business type: Compounder · scaling but economically observable
Size is the strategy's, set against its own position and exposure limits.
At $22.26, CAI requires a 43% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 85%.
The disagreement with the market on CAI is about volume and ASP compounding, not about terminal margin: the terminal margin assumption (16.5%) sits close to the as-filed TTM operating margin (15.48%) and requires only G&A leverage, whereas the growth term moves the answer by 58pp across its admissible window set.
The strongest argument against this view: All of CAI's reported profitability is an accounting estimate of variable consideration on claims already submitted: revenue is booked at an estimated collectible amount per payer portfolio, and $82.4m of TTM revenue -- 53.8% of TTM operating income, and more than 100% of 1H-2026 operating income -- is upward revision of that estimate for services delivered in PRIOR periods.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | The disagreement with the market on CAI is about volume and ASP compounding, not about terminal margin: the terminal margin assumption (16.5%) sits close to the as-filed TTM operating margin (15.48%) and requires only G&A leverage, whereas the growth term moves the answer by 58pp across its admissible window set. |
| What do we forecast? | Revenue growth of 85% demonstrated; a terminal operating margin of 16%; an exit multiple of 8.3x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is +42.0 percentage points. |
| What is it worth? | Twelve-month target $26.37, +18% from the struck price. Scenario-weighted expected return net of costs +10.9%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| every 10-Q from Q3-2026, and the FY2026 10-K | 'adjustments to revenue related to services delivered in prior… | Neither leg of the condition opposite is met at this date | Prior-period revenue adjustments exceed 12% of total revenue in any quarter, OR turn NEGATIVE in any quarter |
| quarterly from Q3-2026 | Blended ASP as stated on the earnings call / in the deck | Blended clinical ASP at or above $3,500 in any quarter | Blended clinical ASP below $3,500 in any quarter |
| quarterly from Q3-2026 | Clinical cases completed, as disclosed each quarter | Neither leg of the condition opposite is met at this date | Clinical case volume growth below +10% year-over-year for two consecutive quarters |
| 1 May 2026 | Issued annual guidance; CMS/MolDX rate determinations | FY2027 revenue guidance issued at or above $1.15bn, or an adverse PAMA / MolDX rate action on the primary WES/WTS codes | FY2027 revenue guidance issued below $1.15bn, or an adverse PAMA / MolDX rate action on the primary WES/WTS codes |
All of CAI's reported profitability is an accounting estimate of variable consideration on claims already submitted: revenue is booked at an estimated collectible amount per payer portfolio, and $82.4m of TTM revenue -- 53.8% of TTM operating income, and more than 100% of 1H-2026 operating income -- is upward revision of that estimate for services delivered in PRIOR periods. The permanent-loss mechanism is that the estimate proves to have been extrapolated from a favourable transition window and reverses: the 2025 ASP step came from MI Cancer Seek's FDA approval and the retroactive $8,455 CMS rate, a one-time repricing that cannot repeat, and CAI submitted its data into the three-year PAMA cycle on 1 May 2026 (management's own disclosure on the Q1 call).
Estimated probability 25%, against the 25% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
EV/NTM revenue above 8.65x -- the p75 of CAI's own positive-EBIT-regime multiple history -- which at consensus NTM revenue is roughly $36.4/share. On approach to the $26.37 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | All of CAI's reported profitability is an accounting estimate of variable consideration on claims already submitted: revenue is booked at an estimated collectible amount per payer portfolio, and $82.4m of TTM revenue -- 53.8% of TTM operating income, and more than 100% of 1H-2026 operating income -- is upward revision of that estimate for services delivered in PRIOR periods. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +42.0 percentage points more growth than the price requires. The most important unresolved uncertainty is the permanent-loss mechanism: all of CAI's reported profitability is an accounting estimate of variable consideration on claims already submitted: revenue is booked at an estimated collectible amount per payer portfolio, and $82.4m of TTM revenue -- 53.8% of TTM operating income, and more than 100% of 1H-2026 operating income -- is upward revision of that estimate for services delivered in PRIOR periods. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $19.08, which forces an immediate review.